About this trial

Radiation therapy is a treatment option for many cancers, including prostate cancer. There are different methods/techniques used to deliver radiation therapy, two of which are IMRT and SBRT, both of which are being used in this trial.

Radiation therapy treatment is delivered over a course of a number of weeks with treatment being delivered each working day for approximately 6 weeks for IMRT and at certain daily intervals as appropriate over approximately 2 weeks for SBRT.

With SBRT a larger dose of radiation is delivered in each treatment than with IMRT. This trial aims to discover if SBRT is superior to IMRT in the treatment of localised intermediate risk prostate cancer in terms of genitourinary and gastrointestinal side effects or toxicities. Patients who are eligible for this study will be assigned into either the IMRT or SBRT group on a 1:1 basis.

Patients in both groups will be asked to fill out quality of life questionnaires at certain points during the study.

Patient Profile

For patients with localised intermediate risk prostate cancer.

Where’s this trial being run?

Beacon Hospital

Can I join this study / trial?

The first thing you do is to talk to your doctor and/or the cancer trials research team in your hospital. The contact details for the cancer trials research units in Ireland is here.

Why not Print this page and bring it with you. It will help your doctor and research team advise you.

For more detailed information


Here’s a list of questions you may have for your doctor or local cancer research team.

Summary Data

Name: NRG GU005
Number: CTRIAL-IE 18-02
Full Title:

NRG GU005 Phase III IGRT and SBRT vs IGRT and Hypofractionated IMRT for Localized Intermediate Risk Prostate Cancer

Principal Investigator: Dr Alina Mihai (The Beacon Hospital)
Type: Collaborative

NRG Oncology (International) Cancer Trials Ireland (Ireland)

Recruitment Started: Global: November 2017
Ireland: February 2019
Global Recruitment Target: 622
Ireland Recruitment Target: 6-10 patients per year.